Sugi Predict

Sugi Predict / Compounds / SCHEMBL44176

SCHEMBL44176

SCHEMBL44176

O=C(CCN1C(=O)C=CC1=O)NCCCCC(C(=O)O)N1C(=O)CCC1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 1/20 0.42
▸ HDAC4 P56524 1/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ HDAC7 Q8WUI4 1/20 0.42
▸ HDAC2 Q92769 1/20 0.42
▸ HDAC10 Q969S8 1/20 0.42
▸ HDAC11 Q96DB2 1/20 0.42
▸ HDAC8 Q9BY41 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ HDAC9 Q9UKV0 1/20 0.42
▸ HDAC5 Q9UQL6 1/20 0.42
▸ FOLH1 Q04609 2/20 0.41
▸ ALDH1A1 P00352 3/20 0.39
▸ PKM P14618 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ PTGS1 P23219 4/20 0.36
▸ PTGS2 P35354 4/20 0.36
▸ POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL502079 0.84 PTGS1 (0.47) FOLH1ALDH1A1PKMSMN1; SMN2HPGD
SCHEMBL4738905 0.82 PTGS1 (0.50) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL5135882 0.81 ALB (0.36) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL31648975 0.80 SMN1; SMN2 (0.38) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL29468060 0.80 SMN1; SMN2 (0.38) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL4429188 0.79 ALDH1A1 (0.50) ALDH1A1PKMSMN1; SMN2HPGDHTT
SCHEMBL9094862 0.79 ALB (0.54) FOLH1ALB
SCHEMBL12835617 0.79 TDP1 (0.45) PTGS1PTGS2
SCHEMBL12762382 0.79 TDP1 (0.45) PTGS1PTGS2
SCHEMBL13880795 0.79 PTGS1 (0.40) PKMPTGS1PTGS2POLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180263927-A1 AFFINITY MEDICANT CONJUGATE AF CHEMICALS, LLC (US) 2018-09-20 — — US claimed
EP-2686019-B1 CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANIONIC POLYPEPTIDE FOR THE TREATMENT OF AIDS PASTEUR INSTITUT (FR) 2017-03-01 — — EP claimed
EP-2249873-B1 CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANION FOR THE TREATMENT OF AIDS PASTEUR INSTITUT (FR) 2016-11-16 — — EP claimed
US-9295730-B2 Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanion for the treatment of AIDS INSTITUT PASTEUR (FR) 2016-03-29 — — US claimed
EP-2903450-A1 USE OF AN ION EXCHANGE MEMBRANE TO REMOVE IMPURITIES FROM CELL-BINDING AGENT CYTOTOXIC AGENT CONJUGATES ImmunoGen, Inc. (US) 2015-08-12 — — EP claimed
EP-2904089-A1 USE OF A PVDF MEMBRANE TO PURIFY CELL-BINDING AGENT CYTOTOXIC AGENT CONJUGATES ImmunoGen, Inc. (US) 2015-08-12 — — EP claimed
EP-2478049-B1 A POLYMER SUPPORT UNIV CAPE TOWN (ZA) 2015-02-25 — — EP claimed
EP-2790724-A1 USE OF N-HYDROXYSUCCINIMIDE TO IMPROVE CONJUGATE STABILITY ImmunoGen, Inc. (US) 2014-10-22 — — EP claimed
WO-2014055893-A1 USE OF AN ION EXCHANGE MEMBRANE TO REMOVE IMPURITIES FROM CELL-BINDING AGENT CYTOTOXIC AGENT CONJUGATES IMMUNOGEN, INC. (US) 2014-04-10 — — WO claimed
WO-2014055877-A1 USE OF A PVDF MEMBRANE TO PURIFY CELL-BINDING AGENT CYTOTOXIC AGENT CONJUGATES IMMUNOGEN, INC. (US) 2014-04-10 — — WO claimed
WO-2012135522-A2 PROCESS FOR MANUFACTURING CONJUGATES OF IMPROVED HOMOGENEITY IMMUNOGEN, INC. (US) 2012-10-04 — — WO claimed
WO-2012112708-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES AND METHODS OF PREPARATION IMMUNOGEN, INC. (US) 2012-08-23 — — WO claimed
WO-2012112687-A1 METHODS OF PREPARATION OF CONJUGATES IMMUNOGEN, INC. (US) 2012-08-23 — — WO claimed
WO-2011100403-A1 CD20 ANTIBODIES AND USES THEREOF IMMUNOGEN, INC (US) 2011-08-18 — — WO claimed
WO-2011100398-A1 CD20 ANTIBODIES AND USES THEREOF IMMUNOGEN, INC. (US) 2011-08-18 — — WO claimed
EP-2054439-B1 CD4-RECEPTOR-DERIVED PEPTIDES AND METHOD FOR THE PREPARATION THEREOF PASTEUR INSTITUT (FR) 2011-06-01 — — EP claimed
US-20110105412-A1 CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANION FOR THE TREATMENT OF AIDS UNIVERSITE PARIS-SUD (FR) 2011-05-05 — — US claimed
US-20110015368-A1 CD4-RECEPTOR-DERIVED PEPTIDES AND METHOD FOR THE PREPARATION THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-01-20 — — US claimed
EP-2054439-A1 CD4-RECEPTOR-DERIVED PEPTIDES AND METHOD FOR THE PREPARATION THEREOF INSTITUT PASTEUR (FR) 2009-05-06 — — EP claimed
WO-2008015273-A1 CD4-RECEPTOR-DERIVED PEPTIDES AND METHOD FOR THE PREPARATION THEREOF INSTITUT PASTEUR (FR) 2008-02-07 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105412-A1 CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANION FOR THE TREATMENT OF AIDS CD4, CD40LG, CD40 HDAC3 4235/4885HDAC4 3498/4885HDAC1 3527/4885
US-20110015368-A1 CD4-RECEPTOR-DERIVED PEPTIDES AND METHOD FOR THE PREPARATION THEREOF CD4, GPR180, GPR65 HDAC3 3629/4885HDAC4 3202/4885HDAC1 2740/4885
US-20180263927-A1 AFFINITY MEDICANT CONJUGATE FCER2, HDGF, FCGR2A HDAC3 1808/4885HDAC4 2923/4885HDAC1 2378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.